Table 1.
Parvovirus B19 infected patients; clinical details, B19 virus markers, and associated cytokine alleles
| Acute infection | Follow up | |||
| Clinical manifestation, B19 marker | No. | Allele | No. | Allele |
| Skin rash | 15 | TGFβ1 +869*T† | 0 | |
| Arthritis | 24 | 10 | ||
| Fatigue | 18 | 11 | ||
| Thrombocytopenia | 2 | 2 | ||
| Transient aplastic crisis, hereditary spherocytosis | 1 | 0 | ||
| Lymphadenopathy | 2 | 1 | ||
| Myalgia | 1 | 0 | ||
| Mother with fetal death | 2 | NA | ||
| Serum anti-B19 VP1/2 IgM | 36 | 0 | ||
| Serum anti-B19 VP1/2 IgG | 35 | 35 | ||
| Serum B19 virus DNA | 34 | 9 | IL-6 –174*G‡ | |
| Serum anti-B19 NS1 IgG | 6 | 14 | IFNγ +874*T§ | |
| IL-10 −819/−592*TA¶ | ||||
| TGFβ1 +869*C†† | ||||
†Odds ratio (OR), 4.83; 95% confidence interval (CI), 1.70 to 13.76; p=0.005; ‡OR, 3.44; 95% CI, 0.89 to 13.30; p=0.12; §OR, 2.75; 95% CI, 1.03 to 7.37; p=0.04; ¶OR, 2.89; 95% CI, 0.81 to 11.36; p=0.11; ††OR, 2.19; 95% CI, 0.76 to 6.62; p=0.10.
IFNγ, interferon γ; IL, interleukin; NS1, non-structural protein 1; TGFβ1, transforming growth factor β1; VP, viral protein.